Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
| ▸ | CIT | O14578 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465668 | 0.81 | CCR1 (0.35) | CCR1CYP3A4PIK3C3KCNH2SCN10A | |
| SCHEMBL3465658 | 0.81 | CCR1 (0.33) | CCR1CYP3A4 | |
| SCHEMBL3465531 | 0.81 | CCR1 (0.33) | CCR1CYP3A4 | |
| SCHEMBL3465964 | 0.81 | CCR1 (0.33) | CCR1CYP3A4 | |
| SCHEMBL3466110 | 0.81 | CCR1 (0.36) | CCR1CYP3A4LARS1PIK3C3SCN10A | |
| SCHEMBL3439409 | 0.80 | CCR1 (0.38) | CCR1CYP3A4 | |
| SCHEMBL3465973 | 0.80 | CCR1 (0.38) | CCR1CYP3A4 | |
| SCHEMBL3465203 | 0.79 | CCR1 (0.35) | CCR1CYP3A4 | |
| SCHEMBL3465836 | 0.79 | CCR1 (0.34) | CCR1CYP3A4 | |
| Hydrochloric Acid SCHEMBL567868 | 0.79 | CCR1 (0.37) | CCR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | CCR1 1/4885CYP3A4 1429/4885LARS1 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.